Pyridam Farma Tbk PT
IDX:PYFA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (15.6), the stock would be worth Rp-528.12 (240% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -11.2 | Rp378 |
0%
|
| Industry Average | 15.6 | Rp-528.12 |
-240%
|
| Country Average | 13.5 | Rp-454.64 |
-220%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| ID |
|
Pyridam Farma Tbk PT
IDX:PYFA
|
4.2T IDR | -11.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 25.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 19.7 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 9.2 |
| Median | 13.5 |
| 70th Percentile | 25.7 |
| Max | 1 419 649.1 |
Other Multiples
Pyridam Farma Tbk PT
Glance View
PT Pyridam Farma Tbk engages in the production and development of pharmaceutical medicines, and trading of medical supplies. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,539 full-time employees. The company went IPO on 2001-10-16. The firm operates through two segments: Pharmaceutical Products and Toll Manufacturing Services, and Medical Device Products. Its business consists of production and/or distribution of modern and traditional medicines and distribution of medical devices, such as laboratory equipment and PCR test kits. The company offers products across consumer health, prescription, pyfaesthetic and biomedilab categories. The company produces various kinds of pharmaceuticals products ranging from antibiotics, vitamins and health supplements. The firm offers its products in the form of effervescent tablets, capsules, caplets, syrups and creams. Its prescription production has several properties, such as anti-infection, anti-inflammatory, anti-parkinsonian, anti-epileptic, and other indications. The company provides toll manufacturing services to produce products owned by the Company’s partner companies in accordance with predetermined specifications.
